CLINICAL TRIALS PROFILE FOR SELUMETINIB SULFATE
✉ Email this page to a colleague
All Clinical Trials for selumetinib sulfate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00551070 ↗ | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | Completed | NRG Oncology | Phase 2 | 2007-12-17 | This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT00551070 ↗ | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2007-12-17 | This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT00559949 ↗ | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | Completed | National Cancer Institute (NCI) | Phase 2 | 2007-12-01 | This phase II trial is studying how well selumetinib works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT01085214 ↗ | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | Completed | National Cancer Institute (NCI) | Phase 2 | 2010-03-01 | This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein. |
| NCT01116271 ↗ | Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | Completed | AstraZeneca | Phase 2 | 2010-04-01 | The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival. |
| NCT01166126 ↗ | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | Terminated | National Cancer Institute (NCI) | Phase 2 | 2010-10-01 | The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for selumetinib sulfate
Condition Name
Clinical Trial Locations for selumetinib sulfate
Trials by Country
Clinical Trial Progress for selumetinib sulfate
Clinical Trial Phase
Clinical Trial Sponsors for selumetinib sulfate
Sponsor Name
